for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Poxel SA

POXEL.PA

Latest Trade

7.58EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

4.92

 - 

9.18

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
7.58
Open
--
Volume
--
3M AVG Volume
1.84
Today's High
--
Today's Low
--
52 Week High
9.18
52 Week Low
4.92
Shares Out (MIL)
25.86
Market Cap (MIL)
206.27
Forward P/E
-16.27
Dividend (Yield %)
--

Next Event

Poxel SA Annual Shareholders Meeting

Latest Developments

More

Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results

Poxel Initiates Phase 1B MAD Trial For Nash Drug Candidate

Poxel H1 Net Result Swings to Loss Of 5.8 Million Euros

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Poxel SA

Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The Company cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.

Industry

Biotechnology & Drugs

Contact Info

Imm Le Sunway

259/261 Avenue Jean Jaures

+33.4.37372010

https://www.poxelpharma.com/

Executive Leadership

Pierre Legault

Chairman of the Board

Thomas Kuhn

Chief Executive Officer, Director

Anne Renevot

Chief Financial Officer

Noah D. Beerman

Executive Vice President - Business Development, US Operations

Christophe Abert-Engels

Executive Vice President - Clinical Development & Medical Affairs

Key Stats

1.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.0K
EPS (EUR)

2016

-1.160

2017

-0.970

2018

0.530

2019(E)

-0.260
Price To Earnings (TTM)
14.93
Price To Sales (TTM)
2.76
Price To Book (MRQ)
3.69
Price To Cash Flow (TTM)
15.18
Total Debt To Equity (MRQ)
25.51
LT Debt To Equity (MRQ)
0.64
Return on Investment (TTM)
35.34
Return on Equity (TTM)
15.70

Latest News

BRIEF-Poxel FY Operating Loss Narrows To 21.9 Million Euros

* FY OPERATING LOSS OF EUR 21.9 MILLION VERSUS LOSS OF EUR 24.3 MILLION YEAR AGO

BRIEF-Poxel And ‍Roivant Announce Strategic Agreement For Development And Commercialization Of Imeglimin

* ROIVANT AND POXEL ANNOUNCE STRATEGIC AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN IN U.S., EUROPE, AND ADDITIONAL COUNTRIES WORLDWIDE

BRIEF-Poxel: Q4 Revenues At 5.2 Million Euros

* AS OF DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS WERE €53.4 MILLION ($64.1 MILLION).

BRIEF-Poxel And Sumitomo Dainippon Pharma Announce Initiation Of Phase 3 Program For Imeglimin In Japan

* POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE INITIATION OF PHASE 3 PROGRAM FOR IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN

BRIEF-Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin

* Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries

BRIEF-Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia

* SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES

BRIEF-Poxel announces cash and cash equivalents at 30.0 million euros as of Sept. 30, 2017​

* AS OF SEPTEMBER 30, 2017, CASH AND CASH EQUIVALENTS WERE EUR 30.0 MILLION

BRIEF-Poxel H1 net loss narrows to 9.7 million euros

* H1 NET LOSS EUR 9.7 MILLION VERSUS LOSS OF EUR 12.4 MILLION YEAR AGO

BRIEF-Poxel cash position at June end amounts to EUR 34.9 mln

* AS OF JUNE 30, 2017, CASH AND CASH EQUIVALENTS WERE EUR 34.9 MILLION (USD 39.8 MILLION).

BRIEF-Poxel announces additional positive results for Imeglimin Phase 2b study in Japan

* POXEL ANNOUNCES ADDITIONAL POSITIVE RESULTS FOR IMEGLIMIN PHASE 2B STUDY IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES

BRIEF-Poxel reports positive data on Imeglimin's phase 1

* PHASE 1 DATA IN JAPANESE SUBJECTS DEMONSTRATED IMEGLIMIN WAS SAFE, WELL TOLERATED AND EXHIBITED A SIMILAR PHARMACOKINETIC PROFILE TO WHAT WAS OBSERVED IN CAUCASIAN SUBJECTS

BRIEF-Poxel cash position at March 31 at EUR 38.8 mln

* As of March 31, 2017, cash and cash equivalents were EUR 38.8 million ($42.6 million)

BRIEF-Poxel announces positive top line results for Imeglimin Phase 2b study in Japan for the treatment of Type 2 Diabetes

* Poxel announces positive top line results for Imeglimin Phase 2b study in Japan for the treatment of Type 2 Diabetes

BRIEF-Poxel appoints Anne Renevot as CFO

* Appoints Anne Renevot as CFO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Poxel announces appointment of Anne Renevot as CFO

* Announces appointment of Anne Renevot as Chief Financial Officer

BRIEF-Poxel announces results for QT safety clinical study of Imeglimin

* Announces positive results for thorough QT safety clinical study of Imeglimin

BRIEF-Poxel appoints Christophe Arbet-Engels as Chief Medical Officer

* Announces appointment of Christophe Arbet-Engels, MD, PHD, MBA, as Chief Medical Officer and EVP Late Development & Medical Affairs, based in Boston Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Poxel Q4 cash and cash equivalents at 45.6 million euros

* As of December 31, 2016, cash and cash equivalents were 45.6 million euros ($48.1 million)

BRIEF-Poxel cash position as of September 30 of 51.1 million euros

* As of September 30, 2016, cash and cash equivalents were 51.1 million euros

BRIEF-Poxel presents new data of diabetes studies

* Poxel presents new data on Imeglimin and PXL770 at the European Association for the study of diabetes annual meeting Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up